The verdict
Our read at a glance.
Whether abaloparatide's approved anabolic osteoporosis benefit is understood within that specific high-fracture-risk setting, rather than generalized.
- The signal
- Randomized trials, including the ACTIVE trial, show abaloparatide increases bone density and reduces fractures in osteoporosis. Like teriparatide, it stimulates bone formation rather than only slowing bone loss.
- The unknown
- Its comparative benefit and tolerability versus teriparatide, and how best to sequence it with antiresorptive drugs to keep the bone gains.
- Our read
- A proven bone-building osteoporosis drug, similar in class to teriparatide. It works for its approved high-risk use, and like teriparatide its osteosarcoma boxed warning came from rat data and was later removed.
The mechanism
How it works.
Abaloparatide is a synthetic analog of PTH-related protein (PTHrP) that binds the same PTH-1 receptor on bone-building osteoblasts as parathyroid hormone, but favors the receptor conformation tied to bone formation. Given as a brief daily spike rather than a steady level, that intermittent signal pushes the balance toward making new bone over breaking it down. The result is added bone density and fewer fractures in people with osteoporosis.
Safety & regulatory boundary
The consequential part.
Abaloparatide once carried a boxed warning for a possible osteosarcoma risk based on rat studies, along with a lifetime-use limit. The FDA later removed that boxed warning and the limit. It remains a prescription osteoporosis drug for specific high-risk patients. Tymlos is the approved product and is not the same as compounded or research-labeled abaloparatide, and the approved use does not extend to general wellness or anti-aging claims.
What's next
What we're watching.
Head-to-head data with teriparatide, sequencing with antiresorptive drugs, and long-term safety follow-up.
Context
Why this is discussed.
Abaloparatide is a newer bone-building osteoporosis drug, often compared with teriparatide.
The evidence base
21 cited references.
Regulatory & labels1
Radius Health, Inc. (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · PHASE2 · NOT_YET_RECRUITING · 2026-06-01
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2019-08-14
ClinicalTrials.gov · PHASE4 · ACTIVE_NOT_RECRUITING · 2021-02-01
ClinicalTrials.gov · RECRUITING · 2023-11-25
ClinicalTrials.gov · PHASE4 · COMPLETED · 2020-01-10
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2025-06
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2025-01-02
ClinicalTrials.gov · PHASE2 · TERMINATED · 2022-05-18
Indexed literature (PubMed)12
Ayers C et al. · Ann Intern Med · 2023
Händel MN et al. · BMJ · 2023
Morin SN et al. · JAMA · 2025
Compston JE et al. · Lancet · 2019
Johnston CB et al. · Med Clin North Am · 2020
Reid IR et al. · Lancet · 2022
Eastell R et al. · J Clin Endocrinol Metab · 2019
Ebina K et al. · J Bone Miner Metab · 2025
Feingold KR et al. · 2000
Anderson PA et al. · J Bone Joint Surg Am · 2024
Sølling AS et al. · Annu Rev Med · 2026
Beaudart C et al. · Osteoporos Int · 2025
Keep reading